On February 24, 2022 RS Oncology, LLC, (RSO) a biotechnology company focused on the treatment of patients with malignant pleural effusion (MPE) and mesothelioma, reported the opening of its first-in-human Phase 1/2 clinical trial (MITOPE) at the University Hospitals of Leicester in the U.K (Press release, RS Oncology, FEB 24, 2022, View Source [SID1234608985]). RSO will be evaluating its novel treatment, RSO-021, against mitochondrial PRX3 enzyme, regulating oxidative stress pathways in cancer cells .
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This novel therapeutic approach has proven in pre-clinical studies to significantly reduce tumor burden in malignant mesothelioma and other cancer types by irreversibly binding and inhibiting PRX3 enzyme in the antioxidant signaling network within the mitochondria of malignant cells.
"The RSO team is excited to begin treating patients at The University of Leicester, U.K. The MITOPE trial is a culmination of substantial innovative work completed by our academic collaborators at University of Vermont, College of Medicine and Wake Forest School of Medicine. This trial is an important step in improving treatment options for people suffering from malignant pleural effusion and mesothelioma," stated Jarrett Duncan, RS Oncology’s CEO. "Our novel therapeutic approach has shown pre-clinical efficacy and safety in nearly a dozen cancer types. We eagerly await the clinical data validating RSO-021 as a safe and effective treatment option for patients with cancer. This novel treatment is desperately needed in the clinical community as patients lack effective second line treatment options," added COO and Head of Business Development, George Naumov.
About MITOPE clinical trial
The MITOPE Phase 1/2 clinical trial is a first-in-human study that will evaluate RSO-021 as a treatment for patients suffering from MPE and mesothelioma. RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. The MITOPE trial is planned to open in six UK-based clinical institutions and will recruit patients with the help of Meso UK. For more MITOPE information review View Source or contact [email protected]. The study is supported by NIHR.